High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients

OBJECTIVES: Immunocompromised patients have an increased risk of severe or prolonged COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 days after symptom onset. Data on the effectivity in immunocompromised patients with chronic non-resolving COVID-19 are ur...

Descripción completa

Detalles Bibliográficos
Autores principales: Huygens, Sammy, Gharbharan, Arvind, Serroukh, Yasmina, Snoek, Britt, Franken, Bas, Oude Munnink, Bas B, Van Hagen, P Martin, Bogers, Susanne, Geurtsvankessel, Corine H, Rijnders, Bart J A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320105/
https://www.ncbi.nlm.nih.gov/pubmed/37248664
http://dx.doi.org/10.1093/jac/dkad144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320105/
https://www.ncbi.nlm.nih.gov/pubmed/37248664
http://dx.doi.org/10.1093/jac/dkad144

Ejemplares similares